Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
Patent 5366980 Issued on November 22, 1994. Estimated Expiration Date: 
September 2, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 2, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders Method for reducing emotional lability Patent #: 5206248 InventorApplicationNo. 114845 filed on 09/02/1993US Classes:514/289Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)ExaminersPrimary: Raymond, Richard L.Attorney, Agent or FirmInternational ClassA61K 031/445AbstractThis invention discloses a method for treating human patients suffering from dermatitis, particularly severe dermatitis which does not respond adequately to non-prescription drugs. Such patients are treated using dextromethorphan (DM), an antitussive agent normally used in cough syrup. If the patient is a so-called "extensive metabolizer," an antioxidant drug (such as quinidine) can be coadministered to inhibit the DM-degrading activity of debrisoquin hydroxylase, an enzyme that will rapidly convert DM into its metabolite, dextrorphan. This treatment has been shown to be highly effective in treating severe dermatitis, and in most patients this drug combination causes no significant adverse side effects.Other References
| |
